Organoid of ovarian cancer: genomic analysis and drug screening

Ovarian cancer is the most common malignant tumors of the female reproductive system, and its standard treatments are cytoreductive surgery and platinum-based adjuvant chemotherapy. Great advances have been achieved in novel treatment strategies, including targeted therapy and immunotherapy. However...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, H.-D., Xia, B.-R., Jin, M.-Z., Lou, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316695/
https://www.ncbi.nlm.nih.gov/pubmed/31939100
http://dx.doi.org/10.1007/s12094-019-02276-8
_version_ 1783550473900392448
author Liu, H.-D.
Xia, B.-R.
Jin, M.-Z.
Lou, G.
author_facet Liu, H.-D.
Xia, B.-R.
Jin, M.-Z.
Lou, G.
author_sort Liu, H.-D.
collection PubMed
description Ovarian cancer is the most common malignant tumors of the female reproductive system, and its standard treatments are cytoreductive surgery and platinum-based adjuvant chemotherapy. Great advances have been achieved in novel treatment strategies, including targeted therapy and immunotherapy. However, ovarian cancer has the highest mortality rate among gynecological tumors due to therapeutic resistance and the gap between preclinical data and actual clinical efficacy. Organoids are a 3D culture model that markedly affects gene analysis, drug screening, and drug sensitivity determination of tumors, especially when used in targeted therapy and immunotherapy. In addition, organoid can lead to advances in the preclinical research of ovarian cancer due to its convenient cultivation, good genetic stability, and high homology with primary tumors.
format Online
Article
Text
id pubmed-7316695
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-73166952020-07-01 Organoid of ovarian cancer: genomic analysis and drug screening Liu, H.-D. Xia, B.-R. Jin, M.-Z. Lou, G. Clin Transl Oncol Review Article Ovarian cancer is the most common malignant tumors of the female reproductive system, and its standard treatments are cytoreductive surgery and platinum-based adjuvant chemotherapy. Great advances have been achieved in novel treatment strategies, including targeted therapy and immunotherapy. However, ovarian cancer has the highest mortality rate among gynecological tumors due to therapeutic resistance and the gap between preclinical data and actual clinical efficacy. Organoids are a 3D culture model that markedly affects gene analysis, drug screening, and drug sensitivity determination of tumors, especially when used in targeted therapy and immunotherapy. In addition, organoid can lead to advances in the preclinical research of ovarian cancer due to its convenient cultivation, good genetic stability, and high homology with primary tumors. Springer International Publishing 2020-01-14 2020 /pmc/articles/PMC7316695/ /pubmed/31939100 http://dx.doi.org/10.1007/s12094-019-02276-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Review Article
Liu, H.-D.
Xia, B.-R.
Jin, M.-Z.
Lou, G.
Organoid of ovarian cancer: genomic analysis and drug screening
title Organoid of ovarian cancer: genomic analysis and drug screening
title_full Organoid of ovarian cancer: genomic analysis and drug screening
title_fullStr Organoid of ovarian cancer: genomic analysis and drug screening
title_full_unstemmed Organoid of ovarian cancer: genomic analysis and drug screening
title_short Organoid of ovarian cancer: genomic analysis and drug screening
title_sort organoid of ovarian cancer: genomic analysis and drug screening
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316695/
https://www.ncbi.nlm.nih.gov/pubmed/31939100
http://dx.doi.org/10.1007/s12094-019-02276-8
work_keys_str_mv AT liuhd organoidofovariancancergenomicanalysisanddrugscreening
AT xiabr organoidofovariancancergenomicanalysisanddrugscreening
AT jinmz organoidofovariancancergenomicanalysisanddrugscreening
AT loug organoidofovariancancergenomicanalysisanddrugscreening

Ejemplares similares